The detection of promutagen activation by extracts of cells expressing cytochrome P450IA2 cDNA: preincubation dramatically increases revertant yield in the Ames test.
Two slightly different protocols, the plate incorporation method and the preincubation method, are used in the Ames Salmonella mutagen test. Using a preincubation method, we recently demonstrated efficient activation of a number of food-derived promutagens by extracts of mammalian cells expressing cDNAs of rat-liver cytochrome P450IA2 and of a P450IA2-IA1 hybrid. We report here that, for 2-amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ), 1-aminoanthracene and several other promutagens, preincubation dramatically increased the number of revertant colonies in the Ames test when extracts of cytochrome P450IA2-containing transfected cells or low concentrations of rat-liver extracts were used as the source of activating enzymes. At higher concentrations of rat-liver extract protein, the effect of preincubation was less pronounced. The effect of preincubation was not due to the low protein concentrations in the assays since increasing the total protein concentration did not abolish the requirement for preincubation for the detection of MeIQ activation at low concentrations of rat-liver extract. In experiments where P450IA2 synthesized in transfected cells in culture is used to study promutagen activation, the plate incorporation protocol may seriously underestimate the capacity of cell extracts to activate promutagens. Thus, interlaboratory comparisons become difficult and unnecessarily large quantities of cell extract protein may be needed to detect promutagen activation. Whenever Ames test assays are carried out under conditions where P450 concentration limits revertant yield, it would be prudent to examine both the preincubation and plate incorporation protocol.
Trottier
Y
Y
Centre de Recherche en Cancérologie de l'Université Laval, L'Hôtel-Dieu de Québec, Canada.
Waithe
W I
WI
Anderson
A
A
D016604:Aflatoxin B1 / Q000494:pharmacology; D000873:Anthracenes / Q000494:pharmacology; D002243:Carbolines / Q000494:pharmacology; D019388:Cytochrome P-450 CYP1A2; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology*; D004101:Dihydroxydihydrobenzopyrenes / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005449:Fluorenes / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D008110:Liver Extracts / Q000494:pharmacology; D016296:Mutagenesis / Q000187:drug effects*; D009152:Mutagenicity Tests / Q000379:methods*; D009153:Mutagens / Q000494:pharmacology*; D010088:Oxidoreductases / Q000502:physiology*; D011804:Quinolines / Q000494:pharmacology; D012486:Salmonella typhimurium; D014162:Transfection
D000873:Anthracenes; D002243:Carbolines; D004101:Dihydroxydihydrobenzopyrenes; D005449:Fluorenes; D007093:Imidazoles; D008110:Liver Extracts; D009153:Mutagens; D011804:Quinolines; C017228:benzo(a)pyrene 7,8-dihydrodiol; C012177:2-aminofluorene; C019133:3-amino-1-methyl-5H-pyrido(4,3-b)indole; C006593:2-anthramine; D003577:Cytochrome P-450 Enzyme System; C049584:2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; D016604:Aflatoxin B1; D010088:Oxidoreductases; D019388:Cytochrome P-450 CYP1A2; C036989:2-amino-3,4-dimethylimidazo(4,5-f)quinoline